Lilly Expects Experience To Help Avoid Mistakes Of Pfizer’s Exubera Launch
Executive Summary
Lilly's experience in the diabetes marketplace is one of the factors that fuels company optimism about its AIR inhaled insulin product, for which the company has an NDA submission goal of 2009, CEO Sidney Taurel told the Bear Stearns Healthcare Conference in New York, Sept. 11
You may also be interested in...
As Pfizer Closes Door On Exubera, Has Window Opened For Others?
Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer
As Pfizer Closes Door On Exubera, Has Window Opened For Others?
Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer
Pfizer Plans Exubera “Full Court Press”’ In 2007 After 2006 Stumbles
Pfizer is finally ramping up for a full-scale launch of the inhaled insulin Exubera - targeting primary care physicians and consumers - over one year after the drug was approved by FDA